Blade Clinical Trials

Today, we are advancing a robust pipeline of potential first-in-class, oral, small-molecule therapies for diseases that result from protein deposition (fibrosis) or protein aggregation (neurodegeneration) that disrupt normal cellular, tissue or organ function. This pipeline includes an autotaxin inhibitor and multiple inhibitors of dimeric calpains to treat lung, liver and cardiac fibrosis or neurodegenerative diseases.

Find Clinical Trials Near Me

Study	Description	Study Phase	Status	Trial number
BLD-0409-101	Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics	Phase 1	Complete	NCT04146805
BLD-0409-102	Relative Bioavailability	Phase 1	In Process	NCT04814472
BLD-0409-103	Drug-Drug Interaction with Probe Substrates for CYP450 Enzymes	Phase 1	In Process	NCT04814498
BLD-0409-104	Drug-Drug Interaction with Approved Therapies for IPF	Phase 1	Planned
BLD-0409-203	Idiopathic Pulmonary Fibrosis	Phase 2	Planned